You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMeclofenamic acid
Accession NumberDB00939  (APRD01090)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. [PubChem]
Structure
Thumb
Synonyms
Acide meclofenamique
Acido meclofenamico
Acidum meclofenamicum
CI-583
INF 4668
Meclofenamate
N-(2,6-Dichloro-3-methylphenyl)anthranilic acid
N-(2,6-Dichloro-m-tolyl)anthranilic acid
N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid
External Identifiers
  • CI 583
  • Cl 583
  • INF 4668
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Meclofenamate Sodiumcapsule50 mg/1oralMylan Pharmaceuticals Inc.1986-09-03Not applicableUs
Meclofenamate Sodiumcapsule100 mg/1oralMylan Pharmaceuticals Inc.1986-09-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EthosYung Shin
EucomeU-Liang
MeclomenPfizer
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Meclofenamate sodium
ThumbNot applicableDBSALT001241
Categories
UNII48I5LU4ZWD
CAS number644-62-2
WeightAverage: 296.149
Monoisotopic: 295.016684015
Chemical FormulaC14H11Cl2NO2
InChI KeyInChIKey=SBDNJUWAMKYJOX-UHFFFAOYSA-N
InChI
InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)
IUPAC Name
2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid
SMILES
CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentAminobenzoic acids
Alternative Parents
Substituents
  • Aminobenzoic acid
  • Benzoic acid
  • Aminotoluene
  • Substituted aniline
  • 1,3-dichlorobenzene
  • Benzoyl
  • Toluene
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Aryl halide
  • Aryl chloride
  • Vinylogous amide
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. Also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis.
PharmacodynamicsMeclofenamic acid is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals.
Mechanism of actionThe mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamic acid was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro meclofenamic acid was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamic acid. There is no evidence that meclofenamic acid alters the course of the underlying disease.
Related Articles
AbsorptionRapidly absorbed in man following single and multiple oral doses with peak plasma concentrations occurring in 0.5 to 2 hours. The concomitant administration of antacids (aluminum and magnesium hydroxides) does not interfere with absorption of meclofenamic acid. Unlike most NSAIDs, which when administered with food have a decrease in rate but not in extent of absorption, meclofenamic acid is decreased in both. It has been reported that following the administration of meclofenamic acid capsules one-half hour after a meal, the average extent of bioavailability decreased by 26%, the average peak concentration (Cmax) decreased fourfold and the time to Cmax was delayed by 3 hours.
Volume of distribution
  • 9.1 to 43.2 L
Protein bindingGreater than 99% bound to plasma proteins over a wide drug concentration range.
Metabolism

Hepatic. Meclofenamic acid is extensively metabolized to an active metabolite (Metabolite I; 3-hydroxymethyl metabolite of meclofenamic acid) and at least six other less well characterized minor metabolites. Only Metabolite I has been shown in vitro to inhibit cyclooxygenase activity with approximately one fifth the activity of meclofenamic acid.

Route of eliminationOther metabolites, whose excretion rates are unknown, account for the remaining 35% to 62% of the dose excreted in the urine. The remainder of the administered dose (approximately 30%) is eliminated in the feces (apparently through biliary excretion). Trace amounts of meclofenamate sodium are excreted in human breast milk.
Half lifeIn a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.
Clearance
  • Oral cl=206 mL/min
ToxicityAfter a massive overdose, CNS stimulation may be manifested by irrational behavior, marked agitation and generalized seizures. Following this phase, renal toxicity (falling urine output, rising creatinine, abnormal urinary cellular elements) may be noted with possible oliguria or anuria and azotemia. A 24 year-old male was anuric for approximately one week after ingesting an overdose of 6 to 7 grams of meclofenamate sodium. Spontaneous diuresis and recovery subsequently occurred.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9393
Blood Brain Barrier+0.8668
Caco-2 permeable+0.8398
P-glycoprotein substrateNon-substrate0.806
P-glycoprotein inhibitor INon-inhibitor0.8943
P-glycoprotein inhibitor IINon-inhibitor0.9474
Renal organic cation transporterNon-inhibitor0.9094
CYP450 2C9 substrateNon-substrate0.6402
CYP450 2D6 substrateNon-substrate0.9164
CYP450 3A4 substrateNon-substrate0.6566
CYP450 1A2 substrateInhibitor0.9236
CYP450 2C9 inhibitorInhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.8271
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.558
Ames testNon AMES toxic0.8633
CarcinogenicityNon-carcinogens0.5329
BiodegradationNot ready biodegradable0.9709
Rat acute toxicity3.0345 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9502
hERG inhibition (predictor II)Non-inhibitor0.872
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Quantum pharmics ltd
  • American therapeutics inc
  • Barr laboratories inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Usl pharma inc
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • Parke davis div warner lambert co
Packagers
Dosage forms
FormRouteStrength
Capsuleoral100 mg/1
Capsuleoral50 mg/1
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point248-250U.S. Patent 3,313,848.
water solubility30 mg/LMERCK INDEX (1996)
logP5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00366 mg/mLALOGPS
logP5.11ALOGPS
logP6.09ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)3.79ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity76.45 m3·mol-1ChemAxon
Polarizability28.44 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

U.S. Patent 3,313,848.

General ReferencesNot Available
External Links
ATC CodesM01AG04M02AA18
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.2 KB)
Interactions
Drug Interactions
Drug
AbciximabMeclofenamic acid may increase the anticoagulant activities of Abciximab.
AcebutololMeclofenamic acid may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aceclofenac.
AcenocoumarolMeclofenamic acid may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Meclofenamic acid.
Alendronic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid.
AliskirenMeclofenamic acid may decrease the antihypertensive activities of Aliskiren.
AlprenololMeclofenamic acid may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Meclofenamic acid.
AmikacinMeclofenamic acid may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideMeclofenamic acid may decrease the antihypertensive activities of Amiloride.
AncrodMeclofenamic acid may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Antipyrine.
Antithrombin III humanMeclofenamic acid may increase the anticoagulant activities of Antithrombin III human.
ApixabanMeclofenamic acid may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Apremilast.
ArdeparinMeclofenamic acid may increase the anticoagulant activities of Ardeparin.
ArgatrobanMeclofenamic acid may increase the anticoagulant activities of Argatroban.
ArotinololMeclofenamic acid may decrease the antihypertensive activities of Arotinolol.
AtenololMeclofenamic acid may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meclofenamic acid.
BalsalazideMeclofenamic acid may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Meclofenamic acid.
BecaplerminMeclofenamic acid may increase the anticoagulant activities of Becaplermin.
BefunololMeclofenamic acid may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Meclofenamic acid.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meclofenamic acid.
BenoxaprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Benoxaprofen.
BetaxololMeclofenamic acid may decrease the antihypertensive activities of Betaxolol.
BevantololMeclofenamic acid may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Meclofenamic acid.
BisoprololMeclofenamic acid may decrease the antihypertensive activities of Bisoprolol.
BivalirudinMeclofenamic acid may increase the anticoagulant activities of Bivalirudin.
BopindololMeclofenamic acid may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bromfenac.
BufuralolMeclofenamic acid may decrease the antihypertensive activities of Bufuralol.
BumetanideMeclofenamic acid may decrease the diuretic activities of Bumetanide.
BupranololMeclofenamic acid may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Meclofenamic acid.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Meclofenamic acid.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Meclofenamic acid.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Meclofenamic acid.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Meclofenamic acid.
CarteololMeclofenamic acid may decrease the antihypertensive activities of Carteolol.
CarvedilolMeclofenamic acid may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Meclofenamic acid.
CeliprololMeclofenamic acid may decrease the antihypertensive activities of Celiprolol.
CertoparinMeclofenamic acid may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Meclofenamic acid.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meclofenamic acid.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meclofenamic acid.
CholestyramineCholestyramine can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Meclofenamic acid.
Citric AcidMeclofenamic acid may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Meclofenamic acid.
ColesevelamColesevelam can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineMeclofenamic acid may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with D-Limonene.
Dabigatran etexilateMeclofenamic acid may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinMeclofenamic acid may increase the anticoagulant activities of Dalteparin.
DanaparoidMeclofenamic acid may increase the anticoagulant activities of Danaparoid.
DaunorubicinMeclofenamic acid may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Deferasirox.
DesirudinMeclofenamic acid may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Meclofenamic acid.
DextranMeclofenamic acid may increase the anticoagulant activities of Dextran.
Dextran 40Meclofenamic acid may increase the anticoagulant activities of Dextran 40.
Dextran 70Meclofenamic acid may increase the anticoagulant activities of Dextran 70.
Dextran 75Meclofenamic acid may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Meclofenamic acid.
DicoumarolMeclofenamic acid may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Meclofenamic acid.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Meclofenamic acid.
DihydrostreptomycinMeclofenamic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Meclofenamic acid.
DoxorubicinMeclofenamic acid may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneMeclofenamic acid may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Droxicam.
Edetic AcidMeclofenamic acid may increase the anticoagulant activities of Edetic Acid.
EdoxabanMeclofenamic acid may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Meclofenamic acid.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Meclofenamic acid.
EnoxaparinMeclofenamic acid may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Epirizole.
EpirubicinMeclofenamic acid may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneMeclofenamic acid may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meclofenamic acid.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Meclofenamic acid.
EsmololMeclofenamic acid may decrease the antihypertensive activities of Esmolol.
Etacrynic acidMeclofenamic acid may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Meclofenamic acid.
Ethyl biscoumacetateMeclofenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Meclofenamic acid.
EtofenamateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Meclofenamic acid.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Meclofenamic acid.
FlunixinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meclofenamic acid.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Meclofenamic acid.
Fondaparinux sodiumMeclofenamic acid may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Meclofenamic acid.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Meclofenamic acid.
FramycetinMeclofenamic acid may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideMeclofenamic acid may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Meclofenamic acid.
GentamicinMeclofenamic acid may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Haloperidol.
HeparinMeclofenamic acid may increase the anticoagulant activities of Heparin.
HirulogMeclofenamic acid may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with HMPL-004.
HydralazineMeclofenamic acid may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meclofenamic acid.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meclofenamic acid.
Hygromycin BMeclofenamic acid may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icatibant.
IdarubicinMeclofenamic acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Meclofenamic acid.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Meclofenamic acid.
IndenololMeclofenamic acid may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Meclofenamic acid.
IndoprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Meclofenamic acid.
IsoxicamThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Isoxicam.
KanamycinMeclofenamic acid may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Meclofenamic acid.
LabetalolMeclofenamic acid may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Leflunomide.
LepirudinMeclofenamic acid may increase the anticoagulant activities of Lepirudin.
LevobunololMeclofenamic acid may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Meclofenamic acid.
LithiumThe serum concentration of Lithium can be increased when it is combined with Meclofenamic acid.
LornoxicamThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Meclofenamic acid.
LoxoprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Meclofenamic acid.
LumiracoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meclofenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Meclofenamic acid.
MesalazineMeclofenamic acid may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Meclofenamic acid.
MetamizoleThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Meclofenamic acid.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid.
MetipranololMeclofenamic acid may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid.
MetoprololMeclofenamic acid may decrease the antihypertensive activities of Metoprolol.
MetrizamideMeclofenamic acid may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Meclofenamic acid.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Meclofenamic acid.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Meclofenamic acid.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meclofenamic acid.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Meclofenamic acid.
NadololMeclofenamic acid may decrease the antihypertensive activities of Nadolol.
NadroparinMeclofenamic acid may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Meclofenamic acid.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Meclofenamic acid.
NCX 4016The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with NCX 4016.
NeomycinMeclofenamic acid may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nepafenac.
NetilmicinMeclofenamic acid may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Meclofenamic acid.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meclofenamic acid.
OlsalazineMeclofenamic acid may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Meclofenamic acid.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Meclofenamic acid.
OrgoteinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Orgotein.
OtamixabanMeclofenamic acid may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxaprozin.
OxprenololMeclofenamic acid may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Parecoxib.
ParomomycinMeclofenamic acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololMeclofenamic acid may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateMeclofenamic acid may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Meclofenamic acid.
PhenindioneMeclofenamic acid may increase the anticoagulant activities of Phenindione.
PhenprocoumonMeclofenamic acid may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meclofenamic acid.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meclofenamic acid.
PindololMeclofenamic acid may decrease the antihypertensive activities of Pindolol.
PiretanideMeclofenamic acid may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meclofenamic acid.
PlicamycinMeclofenamic acid may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Meclofenamic acid.
PractololMeclofenamic acid may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Meclofenamic acid.
ProbenecidThe serum concentration of Meclofenamic acid can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Propacetamol.
PropranololMeclofenamic acid may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Meclofenamic acid.
Protein CMeclofenamic acid may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeMeclofenamic acid may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with PTC299.
PuromycinMeclofenamic acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Meclofenamic acid.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Meclofenamic acid.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Meclofenamic acid.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Meclofenamic acid.
ResveratrolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Resveratrol.
ReviparinMeclofenamic acid may increase the anticoagulant activities of Reviparin.
RibostamycinMeclofenamic acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Risedronate.
RivaroxabanMeclofenamic acid may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Meclofenamic acid.
SalicylamideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Meclofenamic acid.
SalsalateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Meclofenamic acid.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Meclofenamic acid.
SeratrodastThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Seratrodast.
SotalolMeclofenamic acid may decrease the antihypertensive activities of Sotalol.
SpectinomycinMeclofenamic acid may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Meclofenamic acid.
SpironolactoneMeclofenamic acid may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with SRT501.
StreptomycinMeclofenamic acid may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinMeclofenamic acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineMeclofenamic acid may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Meclofenamic acid.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Meclofenamic acid.
SulodexideMeclofenamic acid may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Meclofenamic acid.
TacrolimusMeclofenamic acid may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Meclofenamic acid.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Meclofenamic acid.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Meclofenamic acid.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Meclofenamic acid.
TenofovirThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Meclofenamic acid.
TepoxalinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiaprofenic acid.
TiludronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiludronate.
TimololMeclofenamic acid may decrease the antihypertensive activities of Timolol.
TobramycinMeclofenamic acid may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Meclofenamic acid.
TorasemideMeclofenamic acid may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Meclofenamic acid.
TranilastThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Meclofenamic acid.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Meclofenamic acid.
TriamtereneMeclofenamic acid may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meclofenamic acid.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Meclofenamic acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Meclofenamic acid.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Meclofenamic acid.
WarfarinMeclofenamic acid may increase the anticoagulant activities of Warfarin.
XimelagatranMeclofenamic acid may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Meclofenamic acid.
Zoledronic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Perez-Vizcaino F, Lopez-Lopez JG, Santiago R, Cogolludo A, Zaragoza-Arnaez F, Moreno L, Alonso MJ, Salaices M, Tamargo J: Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity. Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L839-48. [PubMed:12225961 ]
  2. Shiels IA, Whitehouse MW: Lyprinol: anti-inflammatory and uterine-relaxant activities in rats, with special reference to a model for dysmenorrhoea. Allerg Immunol (Paris). 2000 Sep;32(7):279-83. [PubMed:11094641 ]
  3. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222 ]
  4. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181 ]
  5. Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993 Mar 25;268(9):6610-4. [PubMed:8454631 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181 ]
  2. Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M: Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens. 2002 Nov;20(11):2239-45. [PubMed:12409963 ]
  3. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222 ]
  4. Narsinghani T, Chaturvedi SC: QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):461-8. Epub 2005 Nov 14. [PubMed:16290292 ]
  5. Smith WL, Meade EA, DeWitt DL: Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7. [PubMed:7825862 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Iron ion binding
Specific Function:
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:
ALOX5
Uniprot ID:
P09917
Molecular Weight:
77982.595 Da
References
  1. Yu XY, Hubbard W, Spannhake EW: Inhibition of canine tracheal smooth muscle by mediators from cultured bronchial epithelial cells. Am J Physiol. 1992 Feb;262(2 Pt 1):L229-34. [PubMed:1539679 ]
  2. Boctor AM, Eickholt M, Pugsley TA: Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38. [PubMed:3020588 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Voltage-gated potassium channel activity
Specific Function:
Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic in...
Gene Name:
KCNQ2
Uniprot ID:
O43526
Molecular Weight:
95846.575 Da
References
  1. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Voltage-gated potassium channel activity
Specific Function:
Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to sy...
Gene Name:
KCNQ3
Uniprot ID:
O43525
Molecular Weight:
96741.515 Da
References
  1. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a signifiant role in regulating T4 flux into and out of the brain (By similarity).
Gene Name:
SLCO1C1
Uniprot ID:
Q9NYB5
Molecular Weight:
78695.625 Da
References
  1. Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW: Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology. 2009 Feb;150(2):1025-32. doi: 10.1210/en.2008-0188. Epub 2008 Oct 9. [PubMed:18845642 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23